PROJECT SUMMARY Age is the greatest risk factor for Alzheimer?s disease (AD). Nevertheless, a majority of individuals do not develop AD by their 9th decade of life. We propose that targeting the endogenous protective mechanisms associated with ?healthy aging? represents a sound scientific paradigm for addressing AD prevention, especially if this can be achieved using a combination of pre-existing FDA approved drugs. Our initial models of human aging identified novel transcriptomic signatures of aging, common in human hippocampus and muscle, prompting us to develop an expanded biobank and an updated assay that integrates both protein coding and long noncoding RNA (lncRNA) data using novel RNA quantification methods, and extensively phenotyped clinical resources. We have utilized this translational bioinformatics strategy and a novel human biobank to produce a robust prototype screen that successfully identified >100 drugs from in silico analysis using the NIH cMAP/LINCS database, including 29 chemical regulators of a proven longevity pathway (PI3K/mTOR, p
|Effective start/end date||9/30/18 → 5/31/20|
- National Institutes of Health: $749,747.00
- National Institutes of Health: $728,812.00
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.